Clinical Trial Update: S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating gemcitabine and erlotinib with or without monoclonal antibody therapy in metastatic pancreatic cancer that is unresectable.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage IV Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-12-05